INZY - Inozyme Pharma, Inc.

QQQ $ 451.52 $ -1.30 (-0.29 %)

DIA $ 399.76 $ 0.64 (0.16 %)

SPY $ 529.24 $ 0.31 (0.06 %)

TLT $ 91.40 $ -0.22 (-0.24 %)

GLD $ 223.63 $ 1.39 (0.63 %)

Previous Close

$ 4.73

Open

$ 4.64

Bid

$ 4.60 x 400

Ask

$ 4.61 x 200

Day's Range

$ 4.58 - $ 4.72

52 Week Range

$ 2.69 - $ 7.80

Volume

218,190

Average Volume

Market Cap

292.18M

Beta (5Y Monthly)

$ 0.97

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-07-2024	03-31-2024	10-Q
2	03-12-2024	12-31-2023	10-K
3	11-07-2023	09-30-2023	10-Q
4	08-08-2023	06-30-2023	10-Q
5	05-09-2023	03-31-2023	10-Q
6	03-22-2023	12-31-2022	10-K
7	11-10-2022	09-30-2022	10-Q
8	08-15-2022	06-30-2022	10-Q
9	05-10-2022	03-31-2022	10-Q
10	03-15-2022	12-31-2021	10-K
11	11-09-2021	09-30-2021	10-Q
12	08-11-2021	06-30-2021	10-Q
13	05-12-2021	03-31-2021	10-Q
14	03-25-2021	12-31-2020	10-K
15	11-12-2020	09-30-2020	10-Q
16	09-03-2020	06-30-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Needham Reiterates Buy on Inozyme Pharma, ...
05/08/2024 10:17:16

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

Inozyme Pharma Q1 EPS $(0.38) Misses $(0.3...
05/07/2024 12:49:33

Inozyme Pharma (NASDAQ:INZY) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0....

12-health-care-stocks-moving-in-mondays-after-market-session

12 Health Care Stocks Moving In Monday's A...
04/29/2024 20:31:14

Needham Reiterates Buy on Inozyme Pharma, ...
04/10/2024 10:43:01

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

why-tilray-brands-shares-are-trading-lower-by-around-22-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Why Tilray Brands Shares Are Trading Lower...
04/09/2024 17:12:29

Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter esti...

B of A Securities Maintains Buy on Inozyme...
04/09/2024 16:38:02

B of A Securities analyst Tazeen Ahmad maintains Inozyme Pharma (NASDAQ:INZY) with a Buy and lowers the price target from $1...

Needham Reiterates Buy on Inozyme Pharma, ...
04/09/2024 11:56:05

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

Inozyme Pharma Announces Topline Data from...
04/08/2024 10:31:36

Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutic...

top-5-health-care-stocks-that-may-plunge-in-march

Top 5 Health Care Stocks That May Plunge I...
03/28/2024 12:30:01

As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as...

Inozyme Pharma To Report Topline Data From...
03/26/2024 12:31:36

- Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m. ET -

HC Wainwright & Co. Maintains Buy on Inozy...
03/13/2024 13:29:55

HC Wainwright & Co. analyst Edward White maintains Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $16 price target.

Inozyme Pharma: Q4 Earnings Insights
03/12/2024 21:50:18

Needham Reiterates Buy on Inozyme Pharma, ...
03/12/2024 16:36:27

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

Inozyme FY23 EPS $(1.37) Vs $(1.78) YoY; C...
03/12/2024 13:00:07

Financial Results for the Year Ended December 31, 2023 Cash Position and Financial Guidance – Cash, cash equivalents, and short...

Wedbush Reiterates Outperform on Inozyme P...
01/30/2024 15:52:19

Wedbush analyst David Nierengarten reiterates Inozyme Pharma (NASDAQ:INZY) with a Outperform and maintains $15 price target.

Needham Reiterates Buy on Inozyme Pharma, ...
11/08/2023 09:52:32

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.

Inozyme Pharma Q3 EPS $(0.29) Beats $(0.32...
11/07/2023 13:33:03

Inozyme Pharma (NASDAQ:INZY) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.32...

Inozyme Pharma Highlights Inclusion Of Gen...
10/10/2023 12:35:28

Inozyme Pharma, Inc. (NASDAQ:INZY) ("Inozyme" or the "Company"), a clinical-stage rare disease biopharmaceutica...

6 Analysts Have This to Say About Inozyme ...
09/27/2023 18:00:32

Needham Reiterates Buy on Inozyme Pharma, ...
09/27/2023 10:31:04

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.